The global anterior uveitis treatment market is anticipated to expand at a substantial CAGR during forecast period, between 2021 and 2028. The growth of the market is attributed to Increasing prevalence of anterior uveitis across the globe.
Request Free Sample Report Here
Uveitis is a group of inflammatory diseases that destroys eye tissues and causes uvea (middle layer of eye) swelling. These diseases can sometimes lead to severe vision loss. The various types of uveitis are posterior uveitis, anterior uveitis, panuveitis uveitis, and intermediate uveitis. Some diseases such as AIDS, multiple sclerosis, rheumatoid arthritis, tuberculosis, and ulcerative colitis increases the risk of uveitis.
Market Trends, Drivers, Restraints, and Opportunities:
• Favorable government regulations and growing geriatric population is estimated to contribute to the market growth during the forecast period.
• Ongoing developments in the applications of products and treatment modalities are expected to provide long term opportunity for the market growth.
• Factors such as lack of knowledge about eye-related diseases, steep prices of medications, unavailability of health insurance in some developing countries, and side effects of medication including watery eyes and irritation are expected to hinder the market growth.
Anterior Uveitis Treatment Market Segment Insights:
Several advantages of corticosteroids over other treatments are driving the segmental growth
Based on treatment types, the global anterior uveitis treatment market can be bifurcated into corticosteroids, cycloplegic agents, anti-tnf agents, and immunosuppressants. The corticosteroids segment held a significant market share, as they are first line therapies for anterior uveitis. Corticosteroids are inexpensive, potent, and act fast.
Online pharmacies segment is expected to register higher CAGR during the forecast period
On the basis of distribution channels, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Online pharmacies segment is expected to expand at a significant CAGR during the forecast period.
North America is expected to account for a significant share of the global market
Based on regions, the global anterior uveitis treatment market is fragmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America held the highest market share and is projected to expand at a moderate CAGR during the forecast period. Growing prevalence of the diseases in the US and presence of key market players in this region is expected to contribute to the regional growth during the forecast period.
Key players in the global anterior uveitis treatment market includes Santen Pharmaceutical Co., Ltd., AbbVie Inc., Novartis AG, Eyegate Pharmaceuticals, Inc., Aldeyra Therapeutics, Inc., Aciont Inc., Clearside Biomedical, Inc., Sirion Therapeutics, Inc., Lux Biosciences, Inc., Bausch & Lomb Incorporated, UCB Biopharma S.P.R.L., EyePoint Pharmaceuticals, Inc., Alimera Sciences Inc., and Regeneron Pharmaceuticals.
About Growth Market Reports:
GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]
Follow Us: LinkedIn | Twitter